• Sichuan Kelun-Biotech flagged two registrational lung cancer studies selected for oral presentation at ASCO 2026 in Chicago on May 29, with abstracts published on May 21.
• In a Phase III first-line trial in PD-L1-positive advanced non-small cell lung cancer, a sacituzumab tirumotecan regimen paired with pembrolizumab extended the period patients lived without disease worsening, lifted tumor response rates, and showed an early survival signal versus pembrolizumab alone.
• The combination carried a higher rate of serious side effects, while treatment stoppages due to adverse events remained limited.
• Kelun-Biotech said China’s drug regulator accepted a priority-review filing for the combination, positioning it as a potential new first-line option if cleared.
• Separately, a pivotal Phase II study of RET inhibitor lunbotinib in RET-fusion positive NSCLC showed durable tumor control in both previously treated and treatment-naive patients, including activity in brain metastases, supporting an NDA accepted for review in China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605212000PR_NEWS_USPR_____CN65477) on May 22, 2026, and is solely responsible for the information contained therein.